{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:17:27Z","timestamp":1754144247275,"version":"3.41.2"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001009","name":"Bristol-Myers Squibb Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.trim.2025.102242","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:13:37Z","timestamp":1747912417000},"page":"102242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Successful use of cemiplimab in a high immunologic risk kidney transplant recipient with metastatic squamous cell carcinoma"],"prefix":"10.1016","volume":"91","author":[{"given":"Elena-Bianca","family":"Barbir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Grande","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Kukla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itunu","family":"Owoyemi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.trim.2025.102242_bb0005","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.mayocp.2022.07.004","article-title":"Skin cancer in solid organ transplant recipients: a review for the nondermatologist","volume":"97","author":"Berman","year":"2022","journal-title":"Mayo Clin. Proc."},{"issue":"17","key":"10.1016\/j.trim.2025.102242_bb0010","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous squamous-cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.trim.2025.102242_bb0015","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.trim.2025.102242_bb0020","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1002\/cncr.33134","article-title":"Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: a single-center analysis","volume":"126","author":"Owoyemi","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.trim.2025.102242_bb0025","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2025.102242_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fneph.2022.1041819","article-title":"Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients","volume":"2","author":"Van Meerhaeghe","year":"2022","journal-title":"Front Nephrol."},{"issue":"4","key":"10.1016\/j.trim.2025.102242_bb0035","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"9","key":"10.1016\/j.trim.2025.102242_bb0040","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 Ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.trim.2025.102242_bb0045","unstructured":"Hanna GJ, Dharanesswaran H, Giobbie-Hurder A, Harran JJ, Liao Z, Pai L, et al. Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma. Journal of Clinical Oncology;JCO.23.01498."},{"issue":"8","key":"10.1016\/j.trim.2025.102242_bb0050","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/S1470-2045(22)00368-0","article-title":"Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study","volume":"23","author":"Carroll","year":"2022","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.trim.2025.102242_bb0055","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol."},{"issue":"25","key":"10.1016\/j.trim.2025.102242_bb0060","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.2017.76.6691","article-title":"Sirolimus for secondary prevention of skin cancer in kidney transplant recipients: 5-year results","volume":"36","author":"Dantal","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.trim.2025.102242_bb0065","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.trim.2025.102242_bb0070","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1038\/s41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.trim.2025.102242_bb0075","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.trim.2025.102242_bb0080","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.13322","article-title":"Immune checkpoint inhibitor therapy for kidney transplant recipients - a review of potential complications and management strategies","volume":"37","author":"Barbir","year":"2024","journal-title":"Transpl. Int."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742500070X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096632742500070X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T10:09:09Z","timestamp":1752574149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096632742500070X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":16,"alternative-id":["S096632742500070X"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2025.102242","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful use of cemiplimab in a high immunologic risk kidney transplant recipient with metastatic squamous cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2025.102242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102242"}}